Phathom Pharmaceuticals, Inc. (PHAT) delivered a return of -0.18% over the past year. Since PHAT does not currently pay dividends, the total return equals the price-only return.

A $10,000 investment in Phathom Pharmaceuticals, Inc. one year ago would be worth $9,982 today, representing a loss of $18.

Phathom Pharmaceuticals, Inc. (PHAT) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For PHAT, the total return equals the price-only return.

No, Phathom Pharmaceuticals, Inc. (PHAT) underperformed the S&P 500 by 25.17 percentage points over the past year. PHAT delivered a total return of -0.18%, compared to the S&P 500's 24.99%. This means a passive S&P 500 index fund outperformed PHAT by 25.17pp during this period.

Phathom Pharmaceuticals, Inc. (PHAT) experienced a maximum drawdown of -48.89% over the past year, declining from its peak on 2026-01-07 to its trough on 2026-06-01. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Here are Phathom Pharmaceuticals, Inc. (PHAT)'s long-term returns with dividends reinvested. Over 10 years, the total return is -55.8% (-7.8% CAGR) — $10,000 would have grown to $4,423. Over 20 years: -55.8% total return (-4.0% CAGR) — $10,000 → $4,423. Over 30 years: -55.8% total return (-2.7% CAGR) — $10,000 → $4,423. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Phathom Pharmaceuticals, Inc.'s best calendar year was 2025 with a total return of 126.3%. Its worst year was 2022 with a total return of -43.8%. This range shows the volatility investors should expect — the difference between the best and worst year is 170.2 percentage points.